Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

LibertarianTreehugger Sep. 16 at 2:26 PM

Japan Approves 15-Second At-Home Injection for Alzheimer’s: https://jlsfund.substack.com/p/japan-approves-15-second-at-home $BIIB $ESALY

0 · Reply

Quantumup Sep. 16 at 11:00 AM

BofA provided its takeaways from their doctor checks on Isembyld's FDA approval -- $SRRK (Buy; $72) $NVS $BIIB - IONS RHHBY - PTCT Here's what BofA had to say: https://x.com/Quantumup1/status/2100177479776247821?s=20

0 · Reply

TalkMarkets Sep. 15 at 6:07 PM

#Healthcare Sector Update After A Tough Week, Looking For Gains Ahead In #Biotech $BIIB $AMGN $AZN $UNH $ABT https://talkmarkets.com/article/healthcare-sector-update-after-a-tough-week-looking-for-gains-ahead-in-biotech-1789495546

0 · Reply

SGL_FGHI Sep. 15 at 2:02 PM

$TGTX Regarding seller AND buyer perspectives -- given the sheer volume of CURRENT AND FUTURE revenues on the line, I anticipate a COMPETITIVE buyout, and the players and proposals could be quite different. Examples: Perhaps $SNY submits an all-cash proposal, this could be quick with no anti-trust questions? $BIIB is financially capable of acquiring TGTX, but it cannot do so through a pure cash offer thus perhaps a structured acquisition of debt financing and stock-for-stock equity swaps more complicated but doable? Different tax paths or outcomes for TGTX’s current shareholders – but all good?

1 · Reply

Quantumup Sep. 14 at 10:18 AM

Raymond James⬆️ $SRRK's PT to $72 vs $65 and reit'd Strong Buy ~ sees rapid ISEMBYLD US uptake—ests. $2.2B revenue on 50% penetration in 2035: $BIIB - IONS $RHHBY - PTCT NVS Truist⬆️Scholar Rock's PT to $76 vs $55 and reit'd Buy ~ Based on its due-diligence including prior KOL checks, they continue to believe in broad uptake of the drug in combination with SMN2. Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2099442394156388539?s=20

0 · Reply

dogDazeSummer Sep. 11 at 2:30 PM

$IFRX Awesome to see short 12.3m this morning. A 32% increase from just 30 days ago (+3m shares). Based on last 10 trading days volume —-it wld take 19.3 days to cover 12.3m The funds who bought did so for a reason —-and around current pricing + / -$2. They buy for 10-20x They bought because $AMGN has an FDA approved drug that used fraud in its datasets. Already removed from UK and Europe, it’s eventually gonna be removed in “litigation friendly” US. The longer it takes, the better for Inflarx. A proven backup is in the wings. #LiverTox optics can’t look great for Amgen. $BIIB $RHHBY $PFE gotta be looking.

0 · Reply

Quantumup Sep. 10 at 4:22 PM

Goldman Sachs reiterated $STOK Buy-$44 after hosting an investor meeting w, Stoke Therapeutics' mgmt (CEO, CPO & CCASP). $BIIB PRAX DRUG OVID HLUBF HLBBF IONS HRMY SUPN UCBJY JAZZ PYCFX ABEO SPHDF ABEO Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/2098084604477391306?s=20

0 · Reply

11thestate Sep. 10 at 2:40 PM

The Biogen ($BIIB) $18.9M settlement deadline is in 14 days (September 24) If you bought shares in 2021, you are likely eligible for the $18.9M recovery fund. This settlement resolves claims that Biogen misled investors regarding Aduhelm’s Medicare coverage, payer support, and commercial launch readiness after FDA approval. File your claim here: https://11th.com/cases/biib-investor-settlement

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”

0 · Reply

11thestate Sep. 9 at 1:20 PM

Biogen ($BIIB) Settlement FAQ: What Investors Need to Know Q: What happened? A: Biogen was accused of misleading investors about aducanumab's clinical trial results and its explanation for why the ENGAGE trial failed. After the FDA Advisory Committee voted 10-0 that the data did not support the drug's effectiveness, $BIIB fell sharply. Q: Am I actually eligible? A: If you bought $BIIB shares between 2019 and 2020, you may be eligible. You don't need to still hold the stock to potentially qualify. Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Check if you're eligible and file a claim: https://11th.com/cases/biogen-investor-settlement

0 · Reply

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

Sep 14, 2026, 9:15 AM EDT - 2 days ago

Biogen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 9, 2026, 9:30 AM EDT - 7 days ago

Biogen Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 3, 2026, 7:30 PM EDT - 13 days ago

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

STOK

Sep 3, 2026, 12:00 AM EDT - 14 days ago

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

Sep 1, 2026, 7:30 AM EDT - 15 days ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Aug 31, 2026, 7:30 PM EDT - 16 days ago

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

Aug 24, 2026, 8:04 AM EDT - 23 days ago

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Aug 24, 2026, 8:00 AM EDT - 23 days ago

LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Aug 13, 2026, 11:15 PM EDT - 4 weeks ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN GILD JNJ LLY MRK UNH

Aug 6, 2026, 6:15 PM EDT - 5 weeks ago

Biogen Completes Acquisition of RayThera Inc.

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Slides: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Quarterly report: Q2 2026

Jul 29, 2026, 6:23 AM EDT - 7 weeks ago

Biogen Cuts FY Adjusted View as Profit Declines

Jul 29, 2026, 6:03 AM EDT - 7 weeks ago

Biogen beats quarterly estimates as newer drugs fuel growth

Jul 29, 2026, 6:02 AM EDT - 7 weeks ago

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Jul 16, 2026, 7:47 AM EDT - 2 months ago

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Jul 15, 2026, 8:15 AM EDT - 2 months ago

Biogen Appoints Michael J. Parini as Chief Legal Officer

Jul 14, 2026, 12:00 PM EDT - 2 months ago

Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026

Jul 14, 2026, 12:00 PM EDT - 2 months ago

Biogen Slides: FY 2026

Jul 14, 2026, 11:15 AM EDT - 2 months ago

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Jul 14, 2026, 9:18 AM EDT - 2 months ago

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed

Jul 14, 2026, 9:15 AM EDT - 2 months ago

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

Jul 13, 2026, 5:36 PM EDT - 2 months ago

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

Jul 13, 2026, 3:02 PM EDT - 2 months ago

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Jul 13, 2026, 8:15 AM EDT - 2 months ago

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Jul 12, 2026, 11:15 AM EDT - 2 months ago

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Jul 1, 2026, 7:18 AM EDT - 2 months ago

Old cancer drug may help restore fertility for certain women

Jun 29, 2026, 6:59 AM EDT - 2 months ago

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Jun 26, 2026, 9:25 AM EDT - 2 months ago

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

APLS

Jun 17, 2026, 7:10 PM EDT - 3 months ago

Biogen to acquire RayThera for $1 billion

Jun 17, 2026, 6:59 PM EDT - 3 months ago

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Jun 17, 2026, 12:30 PM EDT - 3 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 9, 2026, 2:07 PM EDT - 3 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY CVS PFE VZ

Jun 9, 2026, 9:00 AM EDT - 3 months ago

Biogen Transcript: AGM 2026

Jun 4, 2026, 7:30 AM EDT - 3 months ago

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Jun 4, 2026, 1:00 AM EDT - 3 months ago

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Jun 3, 2026, 7:30 AM EDT - 3 months ago

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Jun 3, 2026, 3:30 AM EDT - 3 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV LLY ROP

Jun 1, 2026, 1:30 AM EDT - 3 months ago

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

May 27, 2026, 2:27 AM EDT - 3 months ago

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 21, 2026, 6:17 PM EDT - 3 months ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

May 21, 2026, 6:00 PM EDT - 3 months ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

May 14, 2026, 12:10 PM EDT - 4 months ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

May 14, 2026, 9:07 AM EDT - 4 months ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 8:35 AM EDT - 4 months ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 7:03 AM EDT - 4 months ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 6:59 AM EDT - 4 months ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

LibertarianTreehugger Sep. 16 at 2:26 PM

Japan Approves 15-Second At-Home Injection for Alzheimer’s: https://jlsfund.substack.com/p/japan-approves-15-second-at-home $BIIB $ESALY

0 · Reply

Quantumup Sep. 16 at 11:00 AM

0 · Reply

TalkMarkets Sep. 15 at 6:07 PM

0 · Reply

SGL_FGHI Sep. 15 at 2:02 PM

1 · Reply

Quantumup Sep. 14 at 10:18 AM

0 · Reply

dogDazeSummer Sep. 11 at 2:30 PM

0 · Reply

Quantumup Sep. 10 at 4:22 PM

0 · Reply

11thestate Sep. 10 at 2:40 PM

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

0 · Reply

11thestate Sep. 9 at 1:20 PM

0 · Reply

NetworkNewsWire Sep. 8 at 1:04 PM

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd

0 · Reply

GJ_Rockabilt Sep. 8 at 11:10 AM

In my biased opinion,$BIIB should Buyout $PROK . Never say never.

1 · Reply

LibertarianTreehugger Sep. 4 at 4:09 PM

Four-Year Data Offer New Hope for Children With Dravet Syndrome: https://jlsfund.substack.com/p/four-year-data-offer-new-hope-for $BIIB $STOK

0 · Reply

LibertarianTreehugger Sep. 3 at 4:15 PM

China Approves 15-Second At-Home Injections of Alzheimer’s Drug Leqembi: https://jlsfund.substack.com/p/china-approves-15-second-at-home $BIIB

0 · Reply

Dopamineaddict Sep. 3 at 11:48 AM

$ANVS Buntanetap sits in an ultra-exclusive club in Alzheimer’s development. Most pipeline drugs (including anti-amyloids) only slow neurodegeneration (NfL) relative to placebo. True DUAL-DROPS—slashing both Tau & NfL BELOW baseline simultaneously—are extremely rare. Only 3 contenders hit this bar: 1 Buntanetap ($ANVS) Tech: Oral small-molecule translational inhibitor (APP, Tau, a-syn). - Status: Phase 3 readout / FDA alignment. Simultaneous drops in Tau & NfL. 2 BIIB080 / Diranersen ($BIIB / $IONS) Tech: Tau-targeting ASO. Status: Phase 2 CELIA data completed, moving to Ph3. Cut CSF p-Tau >50% & drove absolute CSF NfL reductions below baseline. 3 NE3107 / Bezisterim ($BVIE) Tech: Oral NF-kB/ERK neuroinflammation blocker. Status: Phase 2/3. Showed rapid 3-mo mean drops below baseline in CSF p-tau181 & plasma NfL. Buntanetap’s oral convenience vs. ASO spinal injections makes $ANVS a unique late-stage play.

1 · Reply

theDIOyears Sep. 3 at 4:44 AM

$BIIB china approval huh?

0 · Reply

jewell69 Sep. 2 at 4:40 PM

$BIIB Biogen. day trade. Like shooting fish in a barrel with candy taken from a baby. 09/02/2026 Sell Edit cost basis method BIIB BIOGEN INC 26 $224.22 $0.13 $5,829.59 More 09/01/2026 Buy BIIB BIOGEN INC 26 $215.15 -$5,593.90

0 · Reply

dogDazeSummer Sep. 1 at 6:32 PM

$IFRX Hot off the press is Oppenheimer today w reiterattion of $9 target on removal of $AMGN Tavenos by MHRA (UK). Heads I win, Tails you lose mentality cited: “US withdrawal process is ongoing. Amgen filed its hearing response to the FDA's proposed Taveneos withdrawal on July 23. ***** The contested process is expected to extend well into 2027, but IFRX remains advantaged under either outcome: withdrawal creates a greenfield, while continued availability lets Amgen build the market for a potentially better-tolerated oral C5aR inhibitor in izicopan.**** How long before Tavneos could be removed from the US market? There is no direct precedent; Tavneos is the first fully approved drug facing withdrawal over pivotal data manipulation.” $BIIB $PFE $RHHBY

1 · Reply

jewell69 Aug. 27 at 4:38 PM

$GPCR very briefly, stifel says buy 5/7 pt 90, 8/6 pt is 90 IDK if they have even ONE drug that they can make money on NOW (besides milestone payments, IF THEY ARE EVEN hooked up with anybody like $LLY or $BIIB stock is down from stratosphere value 93.67 on 1/21/26 last price 12:37 pm edt 8/27/26 49.71

0 · Reply

dogDazeSummer Aug. 25 at 6:38 PM

$IFRX important find and nice share. Either way this goes, $AMGN drug has been severely tainted. This clarifies rationality of zek /vilo both being better short , medium & long term options. regardless of FDA pulling, forever inferior, or causing liver toxicity on an ongoing basis- we’re in drivers seat w all star cast of A list shareholders. This new article sites specific evidence that will be harder to overcome. Also cracking through the 200 day moving average and 10% short interest in the float doesn’t hurt. $CCXI got paid $6B for avacopan, ouch! $BIIB paid $2B for pre clinical. $3-$4B is very reasonable given today’s facts.

0 · Reply

Stocktwits52wHighs Aug. 25 at 6:31 PM

$BIIB printed a new 52-week high today

0 · Reply

11thestate Aug. 25 at 1:37 PM

$BIIB investors there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/biib-investor-settlement

0 · Reply

Market Cap	31.94B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	15.56
Forward PE	17.51
Profit Margin	13.07%
Debt to Equity Ratio	0.39

Volume	606,400
Avg Vol	1,027,624
Day's Range	N/A - N/A
Shares Out	147.75M
Stochastic %K	42%
Beta	0.17
Analysts	Strong Sell
Price Target	$238.35